Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970744 | 0.92 | IDO1 (0.41) | PDPK1SRD5A1SIGMAR1IDO1 | |
| SCHEMBL5256851 | 0.91 | PDPK1 (0.39) | PDPK1SRD5A1SIGMAR1IDO1 | |
| SCHEMBL316316 | 0.88 | SRD5A1 (0.41) | PDPK1SRD5A1SIGMAR1IDO1CYP11B2 | |
| SCHEMBL4904876 | 0.83 | SIGMAR1 (0.43) | SIGMAR1IDO1 | |
| SCHEMBL964878 | 0.77 | PDPK1 (0.36) | PDPK1IDO1 | |
| SCHEMBL11671198 | 0.77 | SRD5A1 (0.55) | PDPK1SRD5A1SIGMAR1IDO1CYP11B2 | |
| Magnesium SCHEMBL31510119 | 0.75 | SRD5A1 (0.53) | PDPK1SRD5A1SIGMAR1IDO1CYP11B2 | |
| SCHEMBL7980704 | 0.74 | PRCP (0.39) | PDPK1SIGMAR1 | |
| SCHEMBL8892901 | 0.72 | PLAU (0.43) | SIGMAR1IDO1HTR1A | |
| SCHEMBL2257437 | 0.72 | PDPK1 (0.43) | PDPK1SRD5A1SIGMAR1IDO1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0035374-A2 | Piperidyl - urea, - thiourea and - guanidine derivatives, and intermediates therefor, processes for preparing them and pharmaceutical compositions containing the derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1981-09-09 | — | — | EP | claimed |
| US-20140142112-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2111402-B1 | AMINOPYRAZOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2111402-A2 | AMINOPYRAZOLE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008086128-A2 | AMINOPYRAZOLE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142112-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CDR2, GRIN1, HRH2 | PDPK1 2047/4885SRD5A1 2277/4885SIGMAR1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.